Cart
sales@molnova.com
RO9021
CAS No. 1446790-62-0
RO9021( —— )
Catalog No. M23611 CAS No. 1446790-62-0
RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 215 | In Stock |
|
| 10MG | 327 | In Stock |
|
| 25MG | 552 | In Stock |
|
| 50MG | 786 | In Stock |
|
| 100MG | 1062 | In Stock |
|
| 500MG | 2142 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRO9021
-
NoteResearch use only, not for human use.
-
Brief DescriptionRO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
-
DescriptionRO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
-
In VitroRO9021 is a highly selective SYK inhibitor with low S-scores of 0.003 for S(99) and 0.015 for S(90), indicating that SYK is the only kinase with 99% competition with RO9021 in a total of 392 tested kinases. RO9021 inhibits anti-IgM induced phosphorylation of BTK, PLCγ2, AKT and ERK, indicating that blockade of SYK kinase activity by RO9021 results in attenuation of BCR downstream signaling cascade. RO9021 selectively suppresses B-cell receptor signaling. RO9021 also displays a similar inhibitory potency (IC50=22.8±1.7 nM) in a FcεR-mediated mast cell activation and degranulation assay.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetSyk
-
RecptorSYK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1446790-62-0
-
Formula Weight355.44
-
Molecular FormulaC18H25N7O
-
Purity>98% (HPLC)
-
SolubilityDMSO:3 mg/mL (8.44 mM; Need ultrasonic)
-
SMILESCc(cc1)c(C)nc1Nc1cc(N[C@H](CCCC2)[C@H]2N)nnc1C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liao C, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
molnova catalog
related products
-
Lanraplenib
Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
-
LM22B-10
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.
-
ASN-002
ASN-002 (Gusacitinib, ASN002) is a novel and potent dual inhibitor of SYK/JAK kinases with IC50 of 5-46 nM in biochemical assays.
